Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis and Crohn's disease: A real-world cohort study
Inflammatory Intestinal Diseases · 2026-11-10
DOI: 10.1159/iid/adeag013 ↗Abstract
Abstract Introduction: Real-world data on long-term outcomes and predictors of vedolizumab (VDZ) persistence in ulcerative colitis (UC) and Crohn’s disease (CD) remain limited. This study aimed to evaluate long-term treatment persistence and identify predictors of VDZ persistence in patients with UC and CD. Methods: This retrospective study included 107 patients (64 UC and 43 CD) treated with VDZ. Treatment persistence was evaluated using the Kaplan–Meier method, and predictors of persistence were analyzed using Cox proportional hazards models. Results: The median observed treatment duration was 507 days in UC and 266 days in CD. The 1-year persistence rates were 69.4% in UC and 47.5% in CD, while the 2-year persistence rates were 60.2% and 32.5%, respectively. In UC, advanced age was significantly associated with lower VDZ persistence in the Cox model (hazard ratio [HR], 1.29; 95% confidence interval [CI] ,1.06–1.58; p = 0.013). Corticosteroid use at initiation, prior tacrolimus use and prior anti-TNF exposure were not identified as predictors of lower persistence. In CD, perianal disease was significantly associated with lower persistence (log-rank p < 0.01) and remained an independent predictor (HR 2.54, 95% CI 1.20–5.39; p = 0.015). Conclusions: Predictors of VDZ persistence were identified in both UC and CD. Age was associated with VDZ persistence in UC, while perianal disease was associated with VDZ persistence in CD. These findings may help guide patient selection and treatment strategies for VDZ in clinical practice.
EUVIMED